Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription Articles published in Oncologist Retrieve available abstracts of 60 articles: HTML format Text format

Single Articles

August 2019
1. SPIGEL DR, Shipley DL, Waterhouse DM, Jones SF, et al
   A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
   Oncologist. 2019 Aug 16. pii: theoncologist.2018-0518.
   PubMed     Text format     Abstract available
   
   
   July 2019
2. TAKAYAMA K, Ichiki M, Tokunaga S, Inoue K, et al
   Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.
   Oncologist. 2019 Jul 22. pii: theoncologist.2019-0513.
   PubMed     Text format     Abstract available
   
   
   May 2019
3. FINTELMANN FJ, Troschel FM, Kuklinski MW, McDermott S, et al
   Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.
   Oncologist. 2019 May 31. pii: theoncologist.2019-0158.
   PubMed     Text format     Abstract available
   
   
   
4. MELOSKY B, Juergens R, Hirsh V, McLeod D, et al
   Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
   Oncologist. 2019 May 28. pii: theoncologist.2019-0027.
   PubMed     Text format     Abstract available
   
   
   
5. LEE JH, Chen HY, Hsu FM, Chen JS, et al
   Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
   Oncologist. 2019 May 24. pii: theoncologist.2019-0152.
   PubMed     Text format     Abstract available
   
   
   
6. FURUTA M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, et al
   Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
   Oncologist. 2019 May 8. pii: theoncologist.2018-0676.
   PubMed     Text format     Abstract available
   
   
   April 2019
7. ZHENG L, Wang Y, Xu Z, Yang Q, et al
   Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
   Oncologist. 2019 Apr 30. pii: theoncologist.2019-0285.
   PubMed     Text format     Abstract available
   
   
   
8. CHIHARA Y, Yoshimura A, Date K, Takemura Y, et al
   Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
   Oncologist. 2019 Apr 30. pii: theoncologist.2019-0290.
   PubMed     Text format     Abstract available
   
   
   
9. DUMA N, Abdel-Ghani A, Yadav S, Hoversten KP, et al
   Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
   Oncologist. 2019 Apr 29. pii: theoncologist.2019-0094.
   PubMed     Text format     Abstract available
   
   
   
10. RYU JS, Lim JH, Lee MK, Lee SJ, et al
    Feasibility of Bronchial Washing Fluid-Based Approach to Early-Stage Lung Cancer Diagnosis.
    Oncologist. 2019 Apr 29. pii: theoncologist.2019-0147.
    PubMed     Text format     Abstract available
    
    
    
11. OTSUBO K, Sakai K, Takeshita M, Harada D, et al
    Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Oncologist. 2019 Apr 25. pii: theoncologist.2019-0101.
    PubMed     Text format     Abstract available
    
    
    
12. PAVAN A, Calvetti L, Dal Maso A, Attili I, et al
    Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Oncologist. 2019 Apr 23. pii: theoncologist.2018-0563.
    PubMed     Text format     Abstract available
    
    
    
13. ZHANG C, Sun X, Dang K, Li K, et al
    Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network.
    Oncologist. 2019 Apr 17. pii: theoncologist.2018-0908.
    PubMed     Text format     Abstract available
    
    
    
14. CRINO L, Bidoli P, Delmonte A, Grossi F, et al
    Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
    Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737.
    PubMed     Text format     Abstract available
    
    
    
15. SEQUIST LV, Gray JE, Harb WA, Lopez-Chavez A, et al
    Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Oncologist. 2019 Apr 11. pii: theoncologist.2018-0695.
    PubMed     Text format     Abstract available
    
    
    March 2019
16. ABDEL KARIM N, Kelly K
    Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
    Oncologist. 2019 Mar 26. pii: theoncologist.2018-0112.
    PubMed     Text format     Abstract available
    
    
    
17. WEN S, Dai L, Wang L, Wang W, et al
    Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Oncologist. 2019 Mar 22. pii: theoncologist.2018-0572.
    PubMed     Text format     Abstract available
    
    
    
18. CHAE YK, Davis AA, Agte S, Pan A, et al
    Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Oncologist. 2019 Mar 13. pii: theoncologist.2018-0433.
    PubMed     Text format     Abstract available
    
    
    
19. PASELLO G, Vicario G, Zustovich F, Oniga F, et al
    From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
    Oncologist. 2019 Mar 7. pii: theoncologist.2018-0712.
    PubMed     Text format     Abstract available
    
    
    February 2019
20. SONBOL MB, Halling KC, Douglas DD, Ross HJ, et al
    A Case of Donor-Transmitted Non-Small Cell Lung Cancer After Liver Transplantation: An Unwelcome Guest.
    Oncologist. 2019 Feb 12. pii: theoncologist.2018-0517.
    PubMed     Text format     Abstract available
    
    
    
21. XIA L, Liu Y, Wang Y
    PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Oncologist. 2019;24.
    PubMed     Text format     Abstract available
    
    
    
22. LU S, Yu Y, Yang Y
    Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
    Oncologist. 2019;24.
    PubMed     Text format     Abstract available
    
    
    January 2019
23. PARK H, Dahlberg SE, Lydon CA, Araki T, et al
    M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
    Oncologist. 2019 Jan 29. pii: theoncologist.2018-0596.
    PubMed     Text format     Abstract available
    
    
    
24. NAKAO A, Hiranuma O, Uchino J, Sakaguchi C, et al
    Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
    Oncologist. 2019 Jan 16. pii: theoncologist.2019-0003.
    PubMed     Text format     Abstract available
    
    
    
25. PATIL PD, Shapiro M, Hashemi Sadraei N, Pennell NA, et al
    An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2019 Jan 2. pii: theoncologist.2018-0857.
    PubMed     Text format     Abstract available
    
    
    December 2018
26. CHALMERS A, Cannon L, Akerley W
    Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
    Oncologist. 2018 Dec 31. pii: theoncologist.2018-0296.
    PubMed     Text format     Abstract available
    
    
    
27. KHOZIN S, Carson KR, Zhi J, Tucker M, et al
    Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Oncologist. 2018 Dec 27. pii: theoncologist.2018-0307.
    PubMed     Text format     Abstract available
    
    
    
28. YOSHIMURA A, Chihara Y, Date K, Tamiya N, et al
    A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2018 Dec 21. pii: theoncologist.2018-0858.
    PubMed     Text format     Abstract available
    
    
    September 2018
29. WU B, Gu X, Zhang Q, Xie F, et al
    Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
    Oncologist. 2018 Sep 26. pii: theoncologist.2018-0150.
    PubMed     Text format     Abstract available
    
    
    August 2018
30. XIONG L, Li R, Sun J, Lou Y, et al
    Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
    Oncologist. 2018 Aug 29. pii: theoncologist.2018-0120.
    PubMed     Text format     Abstract available
    
    
    
31. BUTTIGLIERO C, Shepherd FA, Barlesi F, Schwartz B, et al
    Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089.
    PubMed     Text format     Abstract available
    
    
    
32. XIE L, Nagpal S, Wakelee HA, Li G, et al
    Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
    Oncologist. 2018 Aug 20. pii: theoncologist.2018-0264.
    PubMed     Text format     Abstract available
    
    
    
33. SATO T, Soejima K, Fujisawa D, Takeuchi M, et al
    Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.
    Oncologist. 2018 Aug 17. pii: theoncologist.2017-0329.
    PubMed     Text format     Abstract available
    
    
    
34. RYSKA A, Buiga R, Fakirova A, Kern I, et al
    Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
    Oncologist. 2018 Aug 3. pii: theoncologist.2018-0008.
    PubMed     Text format     Abstract available
    
    
    
35. GREGORC V, Cavina R, Novello S, Grossi F, et al
    NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
    Oncologist. 2018 Aug 3. pii: theoncologist.2018-0292.
    PubMed     Text format     Abstract available
    
    
    
36. KAMATH SD, Kumthekar PU, Kruser TJ, Mohindra NA, et al
    Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.
    Oncologist. 2018 Aug 2. pii: theoncologist.2018-0022.
    PubMed     Text format     Abstract available
    
    
    June 2018
37. TOI Y, Sugawara S, Kawashima Y, Aiba T, et al
    Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
    Oncologist. 2018 Jun 22. pii: theoncologist.2017-0384.
    PubMed     Text format     Abstract available
    
    
    April 2018
38. CHABNER BA, Nabel CS
    Canakinumab and Lung Cancer: Intriguing, but Is It Real?
    Oncologist. 2018 Apr 17. pii: theoncologist.2018-0116.
    PubMed     Text format    
    
    
    
39. LABABEDE O, Meziane MA
    The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0659.
    PubMed     Text format     Abstract available
    
    
    
40. CHU CY, Choi J, Eaby-Sandy B, Langer CJ, et al
    Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0582.
    PubMed     Text format     Abstract available
    
    
    
41. AHLUWALIA MS, Becker K, Levy BP
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0572.
    PubMed     Text format     Abstract available
    
    
    March 2018
42. SAROCCHI M, Grossi F, Arboscello E, Bellodi A, et al
    Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Oncologist. 2018 Mar 22. pii: theoncologist.2017-0452.
    PubMed     Text format     Abstract available
    
    
    
43. SUH JH, Schrock AB, Johnson A, Lipson D, et al
    Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493.
    PubMed     Text format     Abstract available
    
    
    February 2018
44. MARRONE KA, Zhou X, Forde PM, Purtell M, et al
    A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naive Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 27. pii: theoncologist.2017-0465.
    PubMed     Text format     Abstract available
    
    
    
45. VON PAWEL J, Spigel DR, Ervin T, Losonczy G, et al
    Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 7. pii: theoncologist.2017-0690.
    PubMed     Text format     Abstract available
    
    
    January 2018
46. KHOZIN S, Abernethy AP, Nussbaum NC, Zhi J, et al
    Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Oncologist. 2018 Jan 9. pii: theoncologist.2017-0353.
    PubMed     Text format     Abstract available
    
    
    December 2017
47. ODOGWU L, Mathieu L, Goldberg KB, Blumenthal GM, et al
    FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Oncologist. 2017 Dec 14. pii: theoncologist.2017-0425.
    PubMed     Text format     Abstract available
    
    
    
48. OGAWA A, Kondo K, Takei H, Fujisawa D, et al
    Decision-Making Capacity for Chemotherapy and Associated Factors in Newly Diagnosed Patients with Lung Cancer.
    Oncologist. 2017 Dec 6. pii: theoncologist.2017-0187.
    PubMed     Text format     Abstract available
    
    
    September 2017
49. KUDERER NM, Poniewierski MS, Culakova E, Lyman GH, et al
    Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
    Oncologist. 2017 Sep 26. pii: theoncologist.2017-0205.
    PubMed     Text format     Abstract available
    
    
    August 2017
50. PAI-SCHERF L, Blumenthal GM, Li H, Subramaniam S, et al
    FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
    Oncologist. 2017 Aug 23. pii: theoncologist.2017-0078.
    PubMed     Text format     Abstract available
    
    
    
51. STINCHCOMBE TE
    Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.
    Oncologist. 2017 Aug 4. pii: theoncologist.2017-0204.
    PubMed     Text format     Abstract available
    
    
    July 2017
52. HAN Y, Zhang R, Lin G, Zhang K, et al
    Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.
    Oncologist. 2017 Jul 12. pii: theoncologist.2017-0042.
    PubMed     Text format     Abstract available
    
    
    May 2017
53. SCILLA KA, Bentzen SM, Lam VK, Mohindra P, et al
    Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Oncologist. 2017 May 22. pii: theoncologist.2016-0443.
    PubMed     Text format     Abstract available
    
    
    
54. MIYAUCHI E, Inoue A, Usui K, Sugawara S, et al
    Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Oncologist. 2017 May 19. pii: theoncologist.2017-0059.
    PubMed     Text format     Abstract available
    
    
    
55. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Oncologist. 2017 May 15. pii: theoncologist.2016-0331.
    PubMed     Text format     Abstract available
    
    
    
56. BAIK CS, Myall NJ, Wakelee HA
    Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
    Oncologist. 2017 May 9. pii: theoncologist.2016-0458.
    PubMed     Text format     Abstract available
    
    
    April 2017
57. AGGARWAL C, Borghaei H
    Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
    Oncologist. 2017 Apr 13. pii: theoncologist.2016-0345.
    PubMed     Text format     Abstract available
    
    
    
58. NISHIJIMA TF, Shachar SS, Nyrop KA, Muss HB, et al
    Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Oncologist. 2017;22:470-479.
    PubMed     Text format     Abstract available
    
    
    February 2017
59. WANG X, Wang X, Hodgson L, George SL, et al
    Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Oncologist. 2017;22:189-198.
    PubMed     Text format     Abstract available
    
    
    January 2017
60. BARSANTI-INNES B, Hey SP, Kimmelman J
    The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.
    Oncologist. 2017;22:89-96.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: